YKYY's subsidiary YKYY013 injection has received FDA clinical trial approval
YKYY's subsidiary, Beijing YKYY Technology Co., Ltd., has received FDA approval to conduct clinical trials for YKYY013 injection. This drug is used for the treatment of chronic hepatitis B virus infection, utilizing RNA interference technology aimed at inhibiting HBV replication and promoting host immune reconstitution, ultimately achieving functional cure for hepatitis B
According to the Zhitong Finance APP, YKYY (688658.SH) announced that its subsidiary Beijing YKYY Kechuang Pharmaceutical Technology Co., Ltd. (referred to as "YKYY Kechuang") recently received a notification from the U.S. Food and Drug Administration (FDA) regarding the approval of clinical trials for YKYY013 injection for the treatment of chronic hepatitis B virus infection (Study May Proceed Letter, IND No.: 177486).
YKYY013 injection is a chemically synthesized double-stranded siRNA drug with a conjugated N-acetylgalactosamine (GalNAc) ligand, independently developed by YKYY Kechuang and the company's wholly-owned subsidiary Hangzhou Tianlong Pharmaceutical Co., Ltd. It effectively silences the messenger RNA (mRNA) of the hepatitis B virus (HBV) genome transcription through RNA interference, thereby inhibiting the production of HBV pathogenic proteins, suppressing HBV replication, and creating conditions for host immune reconstruction, ultimately achieving functional cure for hepatitis B. It is intended for clinical use in the treatment of chronic hepatitis B virus infection
